Patents

Patents issued for inhibitors of imidazoline receptors

Published in Obesity and Diabetes Week, November 3rd, 2003

Immtech International, Inc., (IMM) announced that the U.S. and Australian patent offices have awarded Immtech's scientific consortium, comprising the University of North Carolina at Chapel Hill (UNC) and its research collaborators, patents that are part of a group of key patent applications on the use of amidine-containing compounds.

The patents cover compounds that are inhibitors of imidazoline receptors. Drugs that target these receptors are potential treatments for diseases such as Alzheimer, type 2 diabetes, hypertension, and depression. Immtech has exclusive licensing rights to the compounds developed by the UNC-led consortium.

Imidazoline...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2003-11-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry